Tezepelumab for the treatment of patients with severe asthma

2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Lenvatinib mesylate in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Aurinia announces the Great Britain marketing authorisation of Lupkynis (voclosporin) for the treatment of lupus nephritis

30 November 2022 - MHRA Approval follows European Commission marketing authorisation of Lupkynis to treat adults with active lupus nephritis in ...

Read more →

Cemiplimab for the first-line treatment of patients wth advanced or metastatic PD-L1 positive non-small-cell lung cancer

1 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Ripretinib for the treatment of patients with an advanced gastro-intestinal stromal tumour after three or more therapies

30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Mepolizumab for the treatment of patients with severe chronic rhinosinusitis with nasal polyps

29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Leo Pharma’s Adtralza approved by MHRA, EC for adolescent atopic dermatitis

29 November 2022 - The MHRA and the European Commission have approved a change to the terms of the marketing ...

Read more →

NICE’s new methods: putting innovation first, but at what cost?

28 November 2022 - Traditionally the gatekeeper to the NHS, NICE has increasingly reoriented its role towards facilitating access to innovative ...

Read more →

Voclosporin with immunosuppressives for the treatment of patients with lupus nephritis

29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Mepolizumab for the treatment of patients with severe hypereosinophilic syndrome

29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer

28 November 2022 - The treatment will be made available immediately through an early access deal with NHS England. ...

Read more →

Joint statement: NICE and SMC/HIS collaboration

25 November 2022 - NICE and SMC/HIS collaboration on the health technology appraisal of tixagevimab–cilgavimab (Evusheld) for preventing COVID-19. ...

Read more →

NICE recommends Rinvoq (upadacitinib) as treatment option for moderately to severely active ulcerative colitis in adults

25 November 2022 - Publication of positive Final Draft Guidance from NICE is supported by data from three clinical studies that ...

Read more →

Junshi Biosciences announces submission of a marketing authorisation application for toripalimab to the UK MHRA

24 November 2022 - Second marketing authorisation application submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialisation. ...

Read more →

New life-extending treatment for rare forms of advanced gastro-oesophageal cancer recommended by NICE

24 November 2022 - Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of ...

Read more →